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between February and May 2005 in a cross-sectional, obser-
vational study. RESULTS: Fourteen global and 57 detailed 
concepts were included in the conceptual model. The test ques-
tionnaire contained 64 items. After cognitive debrieﬁng, 7 items
were excluded. The questionnaire was well-accepted by the
patients in the pilot study. Clinicians were delighted to have a
helpful patient-management tool. The pilot questionnaire con-
tained 52 items in 10 sections (symptoms, allergy in daily life,
motivations for SIT, advantages, constraints, intake, outcomes,
satisfaction, intention, information). The majority of the 211
clinicians reported high patient acceptability and major interest
in using the questionnaire routinely. The items presenting missing
data, not clearly related to a speciﬁc domain, or redundant were
not selected for ﬁnal format and score calculation. The scores
were assessed for internal consistency reliability, construct valid-
ity and predictive validity. CONCLUSION: This instrument
covers the major domains impacting the patient’s persistence in
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OBJECTIVE: To assess the balance between costs and upper 
GI side effects of treatment with celecoxib (a COX-2 speciﬁc
inhibitor) compared with nonspeciﬁc NSAIDs alone, nonspeciﬁc
NSAIDs plus misoprostol, nonspeciﬁc NSAIDs plus histamine-2
receptor antagonists (H2RA), nonspeciﬁc NSAIDs plus proton
pump inhibitors (PPI), and Arthrotec, in The Netherlands.
METHODS: A model was used to convene data from various
sources. The probabilities of GI side effects for celecoxib and
nonspeciﬁc NSAIDs alone were derived from trial data, while 
all other probabilities were derived from published sources.
Resource use was derived from databases and an expert panel.
Calculations were based on 6 months of treatment, and were
from a societal perspective but were limited to direct medical
costs (2004 Euros; €). Distinction was made between risk groups
based on risk factors such as older age, use of corticosteroids
and history of GI events. RESULTS: Treatment with celecoxib
was associated with the lowest number of GI side effects and
related deaths. Assuming an average patient, the total costs per
6 months of therapy were: celecoxib €212, nonspeciﬁc NSAIDs
alone €151, NSAIDs plus misoprostol €227, NSAIDs plus
H2RAs €268, NSAIDs plus PPIs €269, and Arthrotec €171.
Incremental costs per life-year saved for celecoxib compared
with nonspeciﬁc NSAIDs alone were €12,417 for all patients,
and -€760 for high-risk patients. Comparing celecoxib and
Arthrotec, the incremental costs per life-year saved were €32,757
for all patients and €7759 for those at high-risk of GI events.
CONCLUSION: Celecoxib is a more effective and less costly
treatment than nonspeciﬁc NSAIDs plus misoprostol, NSAIDs
plus H2RAs, and NSAIDs plus PPIs. It is cost-effective compared
with nonspeciﬁc NSAIDs alone for patients at medium- to high-
risk of GI events, and also for high-risk patients. Compared with
Arthrotec, celecoxib showed an improving cost-effectiveness
proﬁle with increasing GI risk.
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OBJECTIVES: Total Hip Replacement (THR) is regarded as gold
standard treatment for degenerative hip disease in elderly
patients. Young, active patients, however, are a more challeng-
ing group for THR due to the high risk of revision and associ-
ated complications. In 2002, the National Institute for Health
and Clinical Excellence (NICE) recommended MoM hip resur-
facing as a treatment option for this patient group. An alterna-
tive treatment for these patients is watchful waiting (WW)
whereby patients are maintained on drug-based regimens until
they are old enough to warrant a THR. The aim of this study
was to evaluate the cost-effectiveness of BHR vs. WW in 45–55
year old patients with severe hip damage. For completeness the
cost-effectiveness of BHR vs. THR was assessed in the same
patient group. METHODS: A health economic model was con-
structed to assess the efﬁcacy, cost and health-related quality of
life associated with BHR, WW and THR treatments. Efﬁcacy
data for BHR were obtained from a large, prospective database
(n = 4424), which provided up to 5 years follow-up for individ-
ual BHR patients. Resource use and utility data were obtained
from published sources. The primary outcome from the model
was the cost per quality-adjusted life-year (QALY). RESULTS:
Preliminary results demonstrate that at year 5 BHR has an incre-
mental cost/QALY (ICER) of £1,101 compared to WW and an
ICER of £13,125 compared to THR. Over time the ICER
decreases and BHR becomes dominant (i.e. it is more effective
and costs less) compared to WW and THR by year 20 and 15,
respectively. CONCLUSIONS: This study demonstrates that in
patients aged 45–55 years with severe hip damage, BHR offers
an extremely cost-effective alternative to WW with an equiva-
lent improvement in quality of life to THR. Patients treated with
BHR will beneﬁt from signiﬁcant health gains at an acceptable
cost.
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OBJECTIVES: OA is associated with signiﬁcant disability,
reduced productivity, decreased HRQoL, and increased health
care costs. The objective was to evaluate the cost-effectiveness of
controlled-release oxycodone (CRO) from a societal perspective
incorporating time loss (paid and unpaid work for patients and
friends/relatives). METHODS: Open-label, active-controlled,
randomized, naturalistic 4-month study of effectiveness and 
cost-effectiveness of CRO vs. short-acting opioids. Outcomes,
resource utilization and time loss were collected by telephone.
Quality-adjusted-life-years (QALYs) were calculated from HUI3
scores. Cost-effectiveness was measured as cost/QALYs gained
and cost/patient improved. RESULTS: Patients treated with
CRO compared to short-acting opioids were more productive
